Rossby Financial LCC Raises Stock Holdings in Zoetis Inc. $ZTS

Rossby Financial LCC raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 31.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,866 shares of the company’s stock after acquiring an additional 1,407 shares during the period. Rossby Financial LCC’s holdings in Zoetis were worth $915,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Zoetis by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock worth $6,842,222,000 after acquiring an additional 189,287 shares in the last quarter. Polen Capital Management LLC raised its holdings in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Zoetis by 1.2% during the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after acquiring an additional 78,508 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Zoetis by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock worth $847,293,000 after acquiring an additional 109,791 shares in the last quarter. Finally, Brown Advisory Inc. raised its holdings in shares of Zoetis by 7.6% during the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock worth $725,866,000 after acquiring an additional 312,746 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

ZTS stock opened at $147.57 on Tuesday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The business’s fifty day simple moving average is $148.08 and its two-hundred day simple moving average is $153.52. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $184.40. The firm has a market cap of $65.40 billion, a price-to-earnings ratio of 25.40, a PEG ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter last year, the firm posted $1.56 earnings per share. The business’s revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is presently 34.42%.

Analysts Set New Price Targets

ZTS has been the topic of several recent research reports. UBS Group decreased their price target on Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a report on Monday, October 20th. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler increased their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Finally, Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, Zoetis currently has an average rating of “Hold” and an average price target of $195.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.